Sign In
Buy ILMN
$170.93
+8.38 (+5.16%)
At Close: Jun 03, 2026
Icahn Ramps Up Bets On Genes And Jets: Illumina Stake Jumps 450%, JetBlue Holding Grow 90%
11:28am, Friday, 16'th May 2025
Carl Icahn is making bold moves from the lab to the tarmac.
Illumina To Webcast Upcoming Investor Conference
04:05pm, Wednesday, 14'th May 2025
SAN DIEGO , May 14, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: 41st Annual Bernstein Strategic Decisi
Investing in Illumina (ILMN)? Don't Miss Assessing Its International Revenue Trends
10:21am, Tuesday, 13'th May 2025
Review Illumina's (ILMN) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Illumina DRAGEN v4.4 powers clinical oncology research and multiomic applications
09:15am, Tuesday, 13'th May 2025
Building on reputation for unparalleled performance, latest software delivers even greater accuracy, with 30% improvement in structural variant calling New features include easy-to-use oncology apps,
Illumina Analysts Lower Their Forecasts After Q1 Results
11:28am, Monday, 12'th May 2025
Illumina, Inc. ILMN reported upbeat earnings for the first quarter, but lowered its FY25 guidance, after the closing bell on Thursday.
Illumina: Multiple Headwinds Point To Limited Upside In 2025
10:58pm, Saturday, 10'th May 2025
Illumina faces significant challenges, including revenue declines, margin pressures, and geopolitical hurdles, notably from China and competition from Roche's SBX technology. Q1 2025 results were in l
Illumina Q1 Earnings Top Estimates, Revenues Down Y/Y, Stock Dips
09:50am, Friday, 09'th May 2025
ILMN delivers better-than-expected earnings and revenues in the first quarter of 2025.
Illumina, Inc. (ILMN) Q1 2025 Earnings Call Transcript
09:01pm, Thursday, 08'th May 2025
Illumina, Inc. (NASDAQ:ILMN ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Brian Blanchett - Interim Head of Investor Relations Jacob Thaysen - Chief Executive Officer
Illumina (ILMN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
08:30pm, Thursday, 08'th May 2025
Although the revenue and EPS for Illumina (ILMN) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street
Illumina (ILMN) Tops Q1 Earnings and Revenue Estimates
07:00pm, Thursday, 08'th May 2025
Illumina (ILMN) came out with quarterly earnings of $0.97 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $0.09 per share a year ago.
Unveiling Illumina (ILMN) Q1 Outlook: Wall Street Estimates for Key Metrics
10:21am, Monday, 05'th May 2025
Beyond analysts' top -and-bottom-line estimates for Illumina (ILMN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarte
Illumina (ILMN) Earnings Expected to Grow: Should You Buy?
11:07am, Thursday, 01'st May 2025
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Illumina and Ovation.io launching first-of-kind GLP-1 dataset to accelerate new therapy development
09:15am, Thursday, 01'st May 2025
First real-world dataset with integrated clinical and multiomic insights from 25,000 patients treated with GLP-1 therapies Dataset will advance development of GLP-1 therapies in new indications and ac
Resmed Names Salli Schwartz as Chief Investor Relations Officer
05:00pm, Monday, 21'st Apr 2025
Former Illumina, MSCI, and Moody's executive brings extensive experience leading engagement with the global investment community Former Illumina, MSCI, and Moody's executive brings extensive experienc
Dublin, April 18, 2025 (GLOBE NEWSWIRE) -- The "Innovation Insights: Target validation for genetic targets" report has been added to ResearchAndMarkets.com's offering.
